Notably, postmenopausal patients with high HCCS expression exhibited significantly worse survival outcomes compared to premenopausal patients (p < 0.0001) (Figure 6g), suggesting a possible role of HCCS in modulating disease progression in postmenopausal breast cancer patients. This evidence concerns the gene HCCS and breast carcinoma.